Cargando…
Resistance to the c-Met inhibitor KRC-108 induces the epithelial transition of gastric cancer cells
Investigation of the mechanisms of resistance to targeted therapies is essential as resistance acquired during treatment may lead to relapse or refractoriness to the therapy. Our previous study identified the small molecule KRC-108 as a result of efforts to find an anticancer agent with c-Met-inhibi...
Autores principales: | KIM, DONG CHUL, PARK, KYEONG RYANG, JEONG, YEON JI, YOON, HYONOK, AHN, MI-JEONG, RHO, GYU-JIN, LEE, JONGKOOK, GONG, YOUNG-DAE, HAN, SUN-YOUNG |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4734112/ https://www.ncbi.nlm.nih.gov/pubmed/26893681 http://dx.doi.org/10.3892/ol.2015.4029 |
Ejemplares similares
-
Characterization of KRC-108 as a TrkA Kinase Inhibitor with Anti-Tumor Effects
por: Lee, Hyo Jeong, et al.
Publicado: (2022) -
Characterization of the aminopyridine derivative KRC-180 as a JAK2 inhibitor
por: Yoon, Kyoung Bin, et al.
Publicado: (2017) -
Schnurri-3 (KRC) Interacts with c-Jun to Regulate the IL-2 Gene in T Cells
por: Oukka, Mohamed, et al.
Publicado: (2004) -
Acceleration of Mesenchymal-to-Epithelial Transition (MET) during Direct Reprogramming Using Natural Compounds
por: Seo, Ji-Hye, et al.
Publicado: (2022) -
Discovery of an Indirubin Derivative as a Novel c-Met Kinase Inhibitor with In Vitro Anti-Tumor Effects
por: Ndolo, Karyn Muzinga, et al.
Publicado: (2019)